U.S.S.N.: 10/579,605 Case No.: 21350YP

Page No.: 2

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1 (Withdrawn): An isolated nucleic acid molecule comprising a sequence of nucleotides that encodes a rhesus monkey dickkopf-1 (rhDkk-1) protein as set forth in SEQ ID NO:2.

Claim 2 (Cancelled)

Claim 3 (Withdrawn): The isolated nucleic acid molecule of claim 1 wherein the nucleic acid is DNA.

Claim 4 (Withdrawn): The isolated nucleic acid molecule of claim 1 wherein the nucleic acid is mRNA.

Claim 5 (Withdrawn): The isolated nucleic acid molecule of claim 1 wherein the nucleic acid is cDNA.

Claim 6 (Withdrawn): The isolated nucleic acid molecule of claim 1 wherein the sequence of nucleotides comprises the sequence of nucleotides set forth in SEQ ID NO:1.

Claim 7 (Withdrawn): A vector comprising the nucleic acid molecule of claim 1.

Claim 8 (Withdrawn): A host cell comprising the vector of claim 7.

Claim 9 (Withdrawn): A process for expressing a rhesus monkey dickkopf-1 (rhDkk-1) protein in a recombinant host cell, comprising:

- (a) introducing a vector comprising the nucleic acid of claim 1 into a suitable host cell; and,
- (b) culturing the host cell under conditions which allow expression of said rhesus Dkk-1 protein.

Claim 10 (Currently Amended): An isolated and purified rhesus dickkopf-1 (rhDkk-1) polypeptide comprising [[a]] the sequence of amino acids as set forth in SEQ ID NO:2.

Claim 11 (Withdrawn): An antibody that binds specifically to the polypeptide of claim 10

Claim 12 (Original): A method for determining whether an analyte is an antagonist of Dickkopf 1 (Dkk-1) comprising:

(a) providing a polypeptide comprising the extracellular domain of a Dkk-1 receptor;

U.S.S.N.: 10/579,605 Case No.: 21350YP

Page No.: 3

(b) contacting the polypeptide with a rhesus monkey Dkk-1 (rhDkk-1) and the analyte; and

(c) determining whether binding of the rhDkk-1 to the polypeptide is decreased in the presence of the analyte, wherein a decrease in the binding indicates that the analyte is an rhDkk-1 antagonist.

Claim 13 (Original): The method of claim 12, wherein the Dkk-1 receptor is low-density lipoprotein receptor related protein 5 (LRP5) or low density lipoprotein receptor related protein 6 (LRP6).

Claim 14 (Original): The method of claim 12, wherein the Dkk-1 receptor is kremen1 or kremen2.

Claim 15 (Original): The method of Claim 12 wherein the rhDkk-1 is labeled.

Claim 16 (Original): The method of Claim 12 wherein the rhDkk-1 is a fusion protein.

Claims 17-38 (Cancelled)